{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:00:54Z","timestamp":1761181254351,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jbspin.2021.105172","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T07:00:56Z","timestamp":1615100456000},"page":"105172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1614-8064","authenticated-orcid":false,"given":"Javier","family":"Narv\u00e1ez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-7146","authenticated-orcid":false,"given":"Teresa","family":"Ot\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Calvo-Al\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Escudero-Contreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Mu\u00f1oz-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4493-1419","authenticated-orcid":false,"given":"Jos\u00e9 Manuel","family":"Rodr\u00edguez-Heredia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Romero-Yuste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma","family":"Vela-Casasempere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Luj\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Baquero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loreto","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2021.105172_bib0290","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s11926-012-0275-1","article-title":"Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis","volume":"14","author":"Demoruelle","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jbspin.2021.105172_bib0295","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s42358-019-0090-8","article-title":"Burden of rheumatoid arthritis on patients\u2019 work productivity and quality of life","volume":"59","author":"Xavier","year":"2019","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105172_bib0300","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2021.105172_bib0305","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.reuma.2010.11.006","article-title":"[Are useful prognostic factors in rheumatoid arthritis?]","volume":"7","author":"Robustillo Villarino","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.jbspin.2021.105172_bib0310","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1007\/s00296-018-4152-8","article-title":"Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence","volume":"38","author":"Munoz-Fernandez","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2021.105172_bib0315","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105172_bib0320","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0197-2456(99)00026-4","article-title":"Assessing the quality of randomized trials: reliability of the Jadad scale","volume":"20","author":"Clark","year":"1999","journal-title":"Control Clin Trials"},{"year":"2011","author":"Howick","series-title":"Oxford CEBM levels of evidence","key":"10.1016\/j.jbspin.2021.105172_bib0325"},{"key":"10.1016\/j.jbspin.2021.105172_bib0330","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2015-207511","article-title":"The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression","volume":"75","author":"Atsumi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105172_bib0335","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/art.23247","article-title":"Clinical remission and\/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study","volume":"59","author":"Burmester","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105172_bib0340","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s10067-014-2731-y","article-title":"Efficacy of golimumab plus methotrexate in methotrexate-naive patients with severe active rheumatoid arthritis","volume":"33","author":"Emery","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105172_bib0345","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1093\/rheumatology\/keu235","article-title":"Short-term efficacy of etanercept plus methotrexate vs. combinations of disease-modifying antirheumatic drugs with methotrexate in established rheumatoid arthritis","volume":"53","author":"Fleischmann","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2021.105172_bib0350","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/ard.2007.085787","article-title":"Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105172_bib0355","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/annrheumdis-2012-202433","article-title":"Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study","volume":"73","author":"Takeuchi","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105172_bib0360","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","article-title":"A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis","volume":"48","author":"Vastesaeger","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2021.105172_bib0365","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2010.139725","article-title":"Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)","volume":"70","author":"Burmester","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105172_bib0370","first-page":"1067","article-title":"Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis","volume":"26","author":"Cuchacovich","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105172_bib0375","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/art.23439","article-title":"Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies","volume":"58","author":"de Vries-Bouwstra","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105172_bib0380","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/rheumatology\/kex489","article-title":"Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2021.105172_bib0385","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13075-015-0912-y","article-title":"Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study)","volume":"18","author":"Heimans","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2021.105172_bib0390","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/art.30596","article-title":"Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment","volume":"63","author":"Lal","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105172_bib0395","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"Sokolove","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105172_bib0400","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1093\/rheumatology\/kes188","article-title":"Comparison of joint destruction between standard- and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study","volume":"51","author":"Tada","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2021.105172_bib0405","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/ard.2009.121160","article-title":"A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study","volume":"69","author":"Visser","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105172_bib0410","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105172_bib0415","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1136\/ard.2011.153734","article-title":"Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression","volume":"70","author":"Aletaha","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105172_bib0420","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/art.20019","article-title":"Once-weekly administration of 50\u00a0mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105172_bib0425","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/art.21678","article-title":"Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial","volume":"54","author":"Smolen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105172_bib0430","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3109\/s10165-010-0325-3","volume":"21","author":"Hashimoto","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105172_bib0435","first-page":"2285","article-title":"Elevated baseline power Doppler discriminates an RA subgroup highly responsive to therapy","volume":"54","author":"Ranganath","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2021.105172_bib0440","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00296-016-3478-3","article-title":"Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study","volume":"36","author":"Akiyama","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2021.105172_bib0445","first-page":"296","article-title":"Rituximab for the treatment of connective tissue disease-associated interstitial lung disease","volume":"32","author":"Chartrand","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.jbspin.2021.105172_bib0450","first-page":"43","article-title":"Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-alpha agents","volume":"35","author":"Detorakis","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105172_bib0455","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pupt.2016.02.002","article-title":"Effect of rituximab on pulmonary function in patients with rheumatoid arthritis","volume":"37","author":"Franzen","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jbspin.2021.105172_bib0460","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years\u2019 experience at a single centre","volume":"56","author":"Md Yusof","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2021.105172_bib0465","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.resinv.2016.03.001","article-title":"Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients","volume":"54","author":"Nakashita","year":"2016","journal-title":"Respir Investig"},{"key":"10.1016\/j.jbspin.2021.105172_bib0470","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Roubille","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105172_bib0475","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1093\/rheumatology\/ker289","article-title":"Non-infectious pulmonary complications of newer biological agents for rheumatic diseases - a systematic literature review","volume":"50","author":"Hadjinicolaou","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2021.105172_bib0480","doi-asserted-by":"crossref","first-page":"e028466","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease-associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jbspin.2021.105172_bib0485","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/rheumatology\/kez337","article-title":"Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2021.105172_bib0490","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/rheumatology\/key298","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"year":"2019","author":"Sociedad Espa\u00f1ola de Reumatolog\u00eda","series-title":"Gu\u00eda de pr\u00e1ctica cl\u00ednica para el manejo de pacientes con artritis reumatoide (GUIPCAR 2016\u201317)","key":"10.1016\/j.jbspin.2021.105172_bib0495"},{"key":"10.1016\/j.jbspin.2021.105172_bib0500","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.semarthrit.2020.08.008","article-title":"Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease","volume":"50","author":"Narvaez","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105172_bib0505","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4236\/ojra.2012.23011","article-title":"Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia","volume":"2","author":"Matteson","year":"2012","journal-title":"Open J Rheumatol Autoimmune Dis"},{"key":"10.1016\/j.jbspin.2021.105172_bib0510","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/imj.14306","article-title":"Rituximab therapy in interstitial lung disease-associated with rheumatoid arthritis","volume":"50","author":"Fui","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.jbspin.2021.105172_bib0515","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/rheumatology\/kez177","article-title":"The lung in a cohort of rheumatoid arthritis patients - an overview of different types of involvement and treatment","volume":"58","author":"Duarte","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2021.105172_bib0520","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/rheumatology\/kez673","article-title":"Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: data from the NEREA Registry","volume":"59","author":"Vadillo","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2021.105172_bib0525","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","article-title":"Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63 patients","volume":"48","author":"Fernandez-Diaz","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105172_bib0530","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14397595.2018.1481566","article-title":"Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept","volume":"29","author":"Mochizuki","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105172_bib0535","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/jcm9010277","article-title":"Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: a multicenter retrospective study","volume":"9","author":"Cassone","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jbspin.2021.105172_bib0540","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.berh.2014.10.016","article-title":"Seronegative rheumatoid arthritis: pathogenetic and therapeutic aspects","volume":"28","author":"Pratt","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105172_bib0545","doi-asserted-by":"crossref","first-page":"26021","DOI":"10.1038\/srep26021","article-title":"Analysis of serum immune markers in seropositive and seronegative rheumatoid arthritis and in high-risk seropositive arthralgia patients","volume":"6","author":"Chalan","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jbspin.2021.105172_bib0550","doi-asserted-by":"crossref","first-page":"e89442","DOI":"10.1371\/journal.pone.0089442","article-title":"The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFalpha agent treatment in patients with rheumatoid arthritis: a meta-analysis","volume":"9","author":"Lv","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jbspin.2021.105172_bib0555","first-page":"991","article-title":"Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs","volume":"29","author":"Narvaez","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105172_bib0560","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/rheumatology\/kep314","article-title":"Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis","volume":"48","author":"Quartuccio","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2021.105172_bib0565","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/ard.2010.148759","article-title":"Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries","volume":"70","author":"Chatzidionysiou","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105172_bib0570","article-title":"The impact of seropositivity on the effectiveness of biologic antirheumatic agents: results from a collaboration of 16 registries","author":"Courvoisier","year":"2020","journal-title":"Rheumatology (Oxford)"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X21000440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X21000440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:28:14Z","timestamp":1761150494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X21000440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1297319X21000440"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2021.105172","relation":{},"ISSN":["1297-319X"],"issn-type":[{"type":"print","value":"1297-319X"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2021.105172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"105172"}}